Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Clinical Genomics Laboratory, |
RCV003448939 | SCV004175895 | likely pathogenic | Treacher Collins syndrome 1 | 2021-06-03 | no assertion criteria provided | clinical testing | The p.Glu1453Lysfs*22 variant in the TCOF1 gene has not been previously reported in association with disease, and was absent from large population databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/). This variant results in a 1 bp deletion and 14 bp insertion, which causes a shift in the protein reading frame, leading to a premature termination codon 22 amino acids downstream. Given the location of this premature termination codon, this variant likely results in either a truncated or absent protein, and heterozygous loss of function is an established mechanism of disease for the TCOF1 gene. Notably, other nearby and downstream frameshift insertions/deletions have been previously reported in association with disease, and has been suggested to be a mutational hotspot (Splendore et al., 2002; Bowman et al., 2012; Vincent et al., 2016). These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, there is sufficient evidence to classify the p.Glu1453Lysfs*22 variant as likely pathogenic for Treacher Collins Syndrome in an autosomal dominant manner based on the information above. [ACMG evidence codes used: PVS1; PM2] |